AOD-9604 is a synthetic peptide fragment derived from human growth hormone (hGH 177–191), developed primarily for research into fat metabolism and weight management. It attracted significant attention because it was designed to reproduce some of growth hormone’s fat-mobilizing activity without its broader growth-promoting effects.
Unlike many newer research peptides, AOD-9604 has actually been investigated in human clinical trials, although its development as an anti-obesity drug was ultimately discontinued after a larger trial failed to demonstrate significant weight loss.
Product Information
AOD-9604 is a modified fragment corresponding to the 177–191 region of human growth hormone. Research has focused on its ability to influence lipolysis and fat metabolism without producing the same growth-related effects associated with full-length growth hormone.
Early clinical research produced encouraging weight-loss signals, including a 12-week trial in which 1 mg/day was associated with greater average weight loss than placebo. However, the subsequent 24-week OPTIONS study involving 536 enrolled participants tested 0.25, 0.5, and 1 mg/day and failed to demonstrate a statistically significant weight-loss advantage over placebo.
How Does AOD-9604 Work?
AOD-9604 was designed to stimulate fat-mobilization pathways, particularly lipolysis, while avoiding many of the growth-promoting actions of full-length growth hormone.
AOD-9604 Benefits
Supports Fat-Metabolism Research
AOD-9604 has been extensively investigated for its ability to promote lipolysis and influence fat metabolism. Animal studies showed reductions in body weight and fat accumulation, which helped drive its development as an experimental obesity compound.
Research Into Body-Fat Reduction
Early human trials produced a measurable weight-loss signal, with approximately 2.6 kg of average weight loss reported after 12 weeks at 1 mg/day compared with approximately 0.8 kg with placebo. These findings generated considerable interest in AOD-9604 as a targeted fat-metabolism peptide.
Designed to Avoid Growth-Hormone Effects
A major attraction of AOD-9604 is its design. Researchers sought to retain the lipolytic portion of growth hormone activity without stimulating growth-related pathways, making it fundamentally different from administering full-length HGH.
Continued Interest in Metabolic Research
Although the larger obesity trial was unsuccessful, AOD-9604 remains of interest in research surrounding adipose tissue, lipid metabolism, and body composition. Its development history also provides a useful example of why promising early peptide data do not always translate into successful large-scale clinical outcomes.
AOD-9604 Side Effects
AOD-9604 was generally well tolerated in the clinical development program, with no major safety signal driving discontinuation. Current peptide-community reports commonly mention headache, nausea, fatigue, injection-site irritation, and occasional digestive discomfort, although these reports are not equivalent to controlled safety data.
AOD-9604 Dosage
Human clinical research has used 0.25–1 mg orally once daily in the 24-week OPTIONS study, while an earlier 12-week study investigated 1 mg/day and higher doses. Current peptide-community protocols also commonly report 250–500 mcg administered subcutaneously, although this route is not equivalent to the oral clinical studies.
Research References
Wilding J. AOD-9604 Metabolic. Curr Opin Investig Drugs. 2004;5(4):436-440. PMID: 15134286.
PubMed — AOD-9604 Metabolic
U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee Meeting — AOD-9604 Clinical Effectiveness. 2024.
FDA — AOD-9604 Clinical Trial Data
Purerawz Disclaimer
Purerawz does not sell, manufacture, stock, dispense, or directly supply any of the products discussed on this website. Purerawz is an independent information and affiliate platform. Where available, links may direct readers to independent third-party providers, and Purerawz may receive a commission from qualifying purchases at no additional cost to the reader.
The information provided is for educational and informational purposes only. Dosage figures may reflect published research protocols, clinical trial doses, or reported community use and should not be interpreted as personalized medical instructions. Research findings, particularly those from animal studies or small early-stage human trials, do not necessarily establish that a product is safe or effective for every individual or condition.
